---
schema_version: "secwatch.filing_event.v1"
accession: "0001157523-21-001266"
form_type: "8-K"
ticker: "EWTX"
cik: "0001710072"
company_name: "Edgewise Therapeutics, Inc."
filed_at: "2021-10-28T23:59:59+00:00"
generated_at: "2026-06-28T16:53:01.601184+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Edgewise reports positive Phase 1 MAD results for EDG-5506; Phase 2 in BMD and DMD planned for 2022

## Summary
- EDG-5506 generally well tolerated; no serious adverse events; mild dizziness/somnolence resolved.
- PK data showed muscle concentrations well above efficacious levels from preclinical DMD models.
- PD demonstrated dose-proportional inhibition of involuntary twitch without affecting voluntary strength or cardiac myosin.
- Phase 1b dosing of BMD patients initiated; Phase 2 in BMD expected Q1 2022, DMD H2 2022.
- Follow-on open-label study in BMD planned for Q1 2022 to assess biomarkers over 3 months.

## SEC filing metadata
- accession: 0001157523-21-001266
- form_type: 8-K
- ticker: EWTX
- cik: 0001710072
- company_name: Edgewise Therapeutics, Inc.
- filed_at: 2021-10-28T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1710072/000115752321001266/0001157523-21-001266-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1710072/000115752321001266/a52517172.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001157523-21-001266
- JSON: https://secwatch.observer/filing/0001157523-21-001266.json
- Plain text: https://secwatch.observer/filing/0001157523-21-001266.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.